Crystal Structure of Human Cytochrome P450 2D6*

Cytochrome P450 2D6 is a heme-containing enzyme that is responsible for the metabolism of at least 20% of known drugs. Substrates of 2D6 typically contain a basic nitrogen and a planar aromatic ring. The crystal structure of human 2D6 has been solved and refined to 3.0Å resolution. The structure shows the characteristic P450 fold as seen in other members of the family, with the lengths and orientations of the individual secondary structural elements being very similar to those seen in 2C9. There are, however, several important differences, the most notable involving the F helix, the F-G loop, the B′helix, β sheet 4, and part of β sheet 1, all of which are situated on the distal face of the protein. The 2D6 structure has a well defined active site cavity above the heme group, containing many important residues that have been implicated in substrate recognition and binding, including Asp-301, Glu-216, Phe-483, and Phe-120. The crystal structure helps to explain how Asp-301, Glu-216, and Phe-483 can act as substrate binding residues and suggests that the role of Phe-120 is to control the orientation of the aromatic ring found in most substrates with respect to the heme. The structure has been compared with published homology models and has been used to explain much of the reported site-directed mutagenesis data and help understand the metabolism of several compounds.

[1]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[2]  G. Tucker,et al.  Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. , 1996, The Biochemical journal.

[3]  Francesca Fanelli,et al.  Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4 , 2000, J. Comput. Aided Mol. Des..

[4]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[5]  G. Tucker,et al.  Functional analysis of CYP2D6.31 variant: Homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution , 2005, Proteins.

[6]  H. Barnes,et al.  Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Gordon C K Roberts,et al.  Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite. , 2004, The Biochemical journal.

[8]  N. Vermeulen,et al.  A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. , 1996, Chemical research in toxicology.

[9]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[10]  Nico P E Vermeulen,et al.  Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. , 2003, Journal of medicinal chemistry.

[11]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[12]  M H Tarbit,et al.  Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  J Deisenhofer,et al.  Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. , 1993, Science.

[14]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[15]  E. Szczesna-Skorupa,et al.  Deletion of a conserved tetrapeptide, PPGP, in P450 2C2 results in loss of enzymatic activity without a change in its cellular location. , 1993, Archives of biochemistry and biophysics.

[16]  N. Vermeulen,et al.  Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism. , 2004, Biochemical pharmacology.

[17]  T. Richardson,et al.  Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modification of its N-terminus. , 1997, Archives of biochemistry and biophysics.

[18]  C David Stout,et al.  Structure of Human Microsomal Cytochrome P450 2C8 , 2004, Journal of Biological Chemistry.

[19]  S. Eddy Hidden Markov models. , 1996, Current opinion in structural biology.

[20]  Nico P. E. Vermeulen,et al.  A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building , 1993, J. Comput. Aided Mol. Des..

[21]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.

[22]  Ruben Abagyan,et al.  ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..

[23]  S. Imaoka,et al.  Catalytic specificity of CYP2D isoforms in rat and human. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[24]  M. Ingelman-Sundberg,et al.  The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent. , 2005, Biochemical pharmacology.

[25]  Eric F. Johnson,et al.  The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.

[26]  F. Guengerich,et al.  Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. , 2001, Chemical research in toxicology.

[27]  G N Murshudov,et al.  Use of TLS parameters to model anisotropic displacements in macromolecular refinement. , 2001, Acta crystallographica. Section D, Biological crystallography.

[28]  G J Kleywegt,et al.  Detection, delineation, measurement and display of cavities in macromolecular structures. , 1994, Acta crystallographica. Section D, Biological crystallography.

[29]  R. Skoda,et al.  The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. , 1990, Pharmacology & therapeutics.

[30]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[31]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[32]  D E McRee,et al.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.

[33]  Lars Ridder,et al.  Mechanism and structure-reactivity relationships for aromatic hydroxylation by cytochrome P450. , 2004, Organic & biomolecular chemistry.

[34]  Rebecca C Wade,et al.  Do mammalian cytochrome P450s show multiple ligand access pathways and ligand channelling? , 2005, EMBO reports.

[35]  Michael J. E. Sternberg,et al.  Evidence That Aspartic Acid 301 Is a Critical Substrate-Contact Residue in the Active Site of Cytochrome P450 2D6 (*) , 1995, The Journal of Biological Chemistry.

[36]  Barry C. Jones,et al.  Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics , 1997 .

[37]  Gordon C K Roberts,et al.  Residues Glutamate 216 and Aspartate 301 Are Key Determinants of Substrate Specificity and Product Regioselectivity in Cytochrome P450 2D6* , 2003, The Journal of Biological Chemistry.

[38]  M. S. Kim,et al.  Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity. , 2001, Archives of biochemistry and biophysics.

[39]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. , 1964, The Journal of biological chemistry.

[40]  G. Tucker,et al.  Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[41]  C David Stout,et al.  Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen , 2005, Nature Structural &Molecular Biology.

[42]  W U Primrose,et al.  A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. , 1996, Biochemistry.

[43]  Y. Zhang,et al.  Cumene hydroperoxide-supported demethylation reactions catalyzed by cytochrome P450 2B4 lacking the NH2-terminal sequence. , 1999, Biochemical and biophysical research communications.

[44]  J. S. Miles,et al.  Identification of the primary gene defect at the cytochrome P450 CYP2D locus , 1990, Nature.

[45]  Chris de Graaf,et al.  Cytochrome p450 in silico: an integrative modeling approach. , 2005, Journal of medicinal chemistry.

[46]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[47]  F Peter Guengerich,et al.  Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. , 2003, Biochemistry.

[48]  H. Barnes,et al.  Purification and characterization of recombinant-expressed cytochrome P450 2C3 from Escherichia coli: 2C3 encodes the 6 beta-hydroxylase deficient form of P450 3b. , 1993, Archives of Biochemistry and Biophysics.

[49]  Eric F. Johnson,et al.  The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.

[50]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[51]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[52]  F. Guengerich,et al.  Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. , 1993, Archives of biochemistry and biophysics.

[53]  J. Venhorst,et al.  Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[54]  S. London,et al.  An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution , 1995, Human Genetics.

[55]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Rotation Functions Biological Crystallography Likelihood-enhanced Fast Rotation Functions , 2003 .

[56]  M. Lennard Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. , 1990, Pharmacology & toxicology.

[57]  D. Lewis Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[58]  S A van Acker,et al.  A predictive model for substrates of cytochrome P450-debrisoquine (2D6). , 1992, Chemical research in toxicology.

[59]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[60]  D. Lewis,et al.  Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[61]  G T Tucker,et al.  Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. , 2001, The Biochemical journal.

[62]  Stewart B Kirton,et al.  Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6 , 2002, Proteins.

[63]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[64]  C. Wolf,et al.  A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. , 1997, Archives of biochemistry and biophysics.

[65]  A. Alex,et al.  Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[66]  G. Kleywegt Use of non-crystallographic symmetry in protein structure refinement. , 1996, Acta crystallographica. Section D, Biological crystallography.

[67]  M. Sutcliffe,et al.  Why Is Quinidine an Inhibitor of Cytochrome P450 2D6? , 2005, Journal of Biological Chemistry.

[68]  J Berendzen,et al.  The catalytic pathway of cytochrome p450cam at atomic resolution. , 2000, Science.

[69]  A. Alex,et al.  A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.